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Edited by Peter Tontonoz and Laszlo NagyAbstract Obesity, type 2 diabetes and the metabolic syndrome
are disorders of energy balance, which the AMP-activated pro-
tein kinase (AMPK) regulates both at the cellular and whole
body levels. AMPK switches cells from an anabolic state where
nutrients are taken up and stored, to a catabolic state where they
are oxidized. Drugs that activate AMPK indirectly (metformin
and thiazolidinediones) are now the mainstay of treatment for
type 2 diabetes, but more direct AMPK activators may have few-
er side eﬀects. However, activating mutations in AMPK can
cause heart disease, and it will be important to look for adverse
eﬀects in the heart.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Ventricular pre-excitation1. Introduction – metabolic syndrome and related metabolic
disorders
The metabolic syndrome is a cluster of metabolic abnormal-
ities that are risk factors for cardiovascular disease. Although
there are rival deﬁnitions of the syndrome that diﬀer in detail,
they all involve combinations of insulin resistance or elevated
blood glucose, elevated blood pressure and triglycerides and
reduced high density lipoprotein cholesterol, and abdominal
obesity. Insulin resistance is the condition whereby major or-
gans such as muscle and liver become resistant to the action
of the hormone, leading to increased glucose output from
the liver, and reduced uptake and metabolism of glucose by
other organs. It can often be compensated, at least initially,Abbreviations: ACC, acetyl-CoA carboxylase; AgRP, agouti-related
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doi:10.1016/j.febslet.2007.11.018by elevated insulin secretion from the pancreas. However, if
this compensatory mechanism fails, insulin resistance gives rise
to elevated blood glucose, the hallmark of type 2 diabetes.
Obesity (usually now deﬁned as a body mass index (BMI) of
30 kg m2 or greater) markedly increases the risk of develop-
ing type 2 diabetes. In one large study of female nurses the risk
was 20-fold higher in those with BMI of 30–35 compared with
lean individuals (BMI < 23), and almost 40-fold higher in
those with BMI > 35 [1]. These are very worrying statistics, be-
cause the global population is rapidly becoming more obese.
Insulin resistance and type 2 diabetes increase with age, and
as the average age of the population increases and they become
more obese due to changes in lifestyle, the prevalence of diabe-
tes is rising.
Where does the AMP-activated protein kinase (AMPK) sys-
tem ﬁt in to this? The main premise of this review is that insulin
resistance, type 2 diabetes, the metabolic syndrome and obesity
are all disorders of energy balance. Since the AMPK system is
a major regulator of energy balance at both the cellular and
whole body levels, its roles in these disorders need to be consid-
ered. The role of AMPK in their causation is currently unclear,
although it has recently been reported that the activation of
AMPK during exercise is reduced in obese and type 2 diabetic
humans [2]. Moreover, the role of AMPK activation in the
treatment of these disorders is well established. The evidence
for this will be covered in this review, which will also cover
the role of rare mutations in AMPK subunits in glycogen stor-
age disorders that cause human heart disease.2. The AMPK complex and its orthologues in non-mammalian
eukaryotes
The AMP-activated protein kinase exists as heterotrimeric
complexes comprising catalytic a subunits and regulatory b
and c subunits, with multiple genes encoding each subunit in
mammals (a1, a2, b1, b2, c1, c2, c3) [3]. It appears to be a
rather ancient system, because orthologues of the mammalian
a, b and c subunits are readily found by searching genome
sequences, including those of insects (e.g. Drosophila melano-
gaster), nematodes (e.g. Caenorhabditis elegans), fungi (e.g.
Saccharomyces cerevisiae and Schizosaccharomyces pombe),
plants (e.g. Arabidopsis thaliana and Physcomitrella patens),
and protists (e.g. Giardia lamblia, Trypanosoma brucei, and
Dictyostelium discoideum) (Fig. 1). Genetic studies of ortho-
logues in lower eukaryotes suggest that the system arose as ablished by Elsevier B.V. All rights reserved.
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Fig. 1. Phylogenetic trees of sequences of the a, b and c subunits from AMPK orthologues in diﬀerent eukaryotic species. Alignments were generated
using the ALIGNX programmes in Vector NTI 7.
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ods of starvation. The S. cerevisiae orthologue (the SNF1 com-
plex) is required for the response to starvation for its preferred
carbon source (glucose) and switches on expression of genes
required for metabolism of other carbon sources [4]. It is also
required for sporulation, which allows the organism to with-
stand a period of prolonged starvation. In C. elegans, starva-
tion and other stresses during early development induce the
‘‘Dauer’’ larval form that is sexually immature but lives much
longer than the normal form. Genes encoding the catalytic
subunits of AMPK are required for the normal extension of
lifespan induced by starvation during early development [5],
and for cell cycle arrest of the germ cells during formation of
the Dauer larva [6]. In a primitive plant, the moss Physcomit-
rella patens, the two catalytic subunit genes are required forsurvival in alternate light/dark cycles, but not for growth in
continuous light [7]. Darkness is of course the equivalent of
starvation for a photosynthetic organism.3. Mammalian AMPK – regulation by AMP/ATP and upstream
kinases
As its name suggests, one of the key features of mammalian
AMPK is its activation by 5 0-AMP. As well as this direct allo-
steric eﬀect, which can yield up to 10-fold activation, AMP also
promotes net phosphorylation at a critical threonine residue
(Thr-172) within the kinase domain that can generate a further
100-fold activation, the combined eﬀect being 1000-fold [8].
The major upstream kinase in most cells (Fig. 2) is a complex
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Fig. 2. Regulation of AMPK by AMP, ATP and upstream kinases.
While CaMKKb is switched on by a rise in cytosolic Ca2+, the
LKB1:STRAD:MO25 complex appears to be constitutively active and
phosphorylates AMPK constantly. However, under basal conditions
the phosphate is immediately removed by PP2C. A rise in the cellular
AMP:ATP ratio inhibits dephosphorylation, switching AMPK to the
phosphorylated form, which is also allosterically activated by the
increase in AMP:ATP ratio. The physiological signiﬁcance of activa-
tion by TAK1 remains uncertain at present.
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sory subunits, STRAD and MO25 [9,10], which appears to be
constitutively active [11,12]. It was previously thought that
AMP binding to AMPK both promoted phosphorylation by
LKB1 [9] and inhibited dephosphorylation by protein phospha-
tase-2C (PP2C) [13], but the eﬀect on phosphorylation has
recently been challenged and may have been due to contamina-
tion of the preparations used with traces of PP2C [14]. If this
view is correct, Thr-172 would be continually recycling between
the phospho- and dephospho-forms even under basal condi-
tions, which might appear to be rather wasteful. However, this
mechanism would ensure an extremely sensitive response to
AMP, in which even a slight inhibition of dephosphorylation
would produce a large shift to the phosphorylated, active form.
AMP in eukaryotic cells is usually maintained at very low
levels by the reversible reaction catalyzed by adenylate kinase
(AMP + ATPM 2ADP) which is driven from left to right by
the high ratio of ATP:ADP in a fully energized cell. However,
if the cell experiences some kind of metabolic insult that causes
the ATP:ADP ratio to fall, the adenylate kinase reaction will
be displaced to the left, causing a large increase in AMP and
thus switching on the AMPK system. This eﬀect is accentuated
by the ability of high concentrations of ATP to antagonize
both activating eﬀects of AMP (Fig. 2). Thus, the AMPK sys-
tem is switched on by stresses that interfere with ATP produc-
tion, such as deprivation of cells for glucose or oxygen, or
stresses that accelerate ATP consumption, such as muscle con-
traction [3]. Findings that the activation of AMPK by contrac-
tion is reduced in adenylate kinase-1 knockout (AK1/) mice
[15] are consistent with the idea that AMP is the key signal for
activation of AMPK under these circumstances.
Although activation of AMPK by changes in the cellular
AMP:ATP ratio represents the ‘‘classical’’ mode of regulation,
it is becoming clear that it can also be switched on via AMP-
independent mechanisms. Following the discovery of the
LKB1:STRAD:MO25 complex as the major upstream kinase
[9,10], three groups provided evidence that calmodulin-depen-
dent protein kinase kinase (CaMKK)-a and -b, especially the
latter, could also phosphorylate Thr-172 and thus activate
AMPK in intact cells [16–18]. The CaMKKs are Ca2+- and
calmodulin-dependent kinases that were originally discoveredfor their ability to activate calmodulin-dependent kinases-I
and -IV via phosphorylation at sites that are closely related
in surrounding sequence to that of Thr-172 on the AMPK a
subunits [19]. Experiments in HeLa cells (which are deﬁcient
in LKB1) show that expression of LKB1 is required for activa-
tion of AMPK by treatments that increase the concentration
of AMP or AMP analogues, but that activation by treatment
with calcium ionophores via phosphorylation by CaMKKb
still occurs [16]. This shows that this mechanism can operate
in the absence of any change in cellular AMP. The CaMKKs
are expressed at highest levels in neural tissue [19], and the dis-
tribution of this Ca2+-mediated pathway for AMPK activation
in other cell types is still being investigated. It clearly occurs in
neurones in response to activation of voltage-gated Ca2+ chan-
nels [16], in T lymphocytes in response to stimulation of the
antigen receptor [20], and in endothelial cells in response to
activation of the thrombin receptor, which is coupled via Gq
to release of inositol trisphosphate and hence of Ca2+ from
the endoplasmic reticulum [21].
A third potential upstream kinase (Fig. 2) is TAK1, which
activates the SNF1 complex (the yeast orthologue of AMPK)
when expressed in S. cerevisiae, and also activates AMPK in
cell-free assays [22]. However, whether this is physiologically
relevant remains unclear at present.
Interestingly, AMPK complexes containing the a2 isoform
appear to be almost completely LKB1-dependent in vivo,
whereas a1 complexes appear to be activated by both LKB1
and by other upstream kinases. For example, in mice with a
muscle-speciﬁc conditional LKB1 knockout, a2 activity was
completely eliminated in both skeletal and cardiac muscle,
even after treatments that normally stimulate the activity
(in situ electrical stimulation in skeletal muscle and ischaemia
in cardiac muscle). By contrast, a1 activity was reduced but
not eliminated in both muscles, and in cardiac muscle was still
stimulated by ischaemia [23,24]. Whether CaMKKs are
responsible for the residual, LKB1-independent activity of a1
complexes is not completely resolved, although there is evi-
dence using pharmacological inhibitors that CaMKKs could
be responsible for activation of AMPK in skeletal muscle dur-
ing electrical stimulation of low intensity or short duration
[25,26]. The LKB1 pathway may become more signiﬁcant after
longer and more intense contractions, when ATP depletion is
likely to be more marked. However, the interpretation of re-
sults using pharmacological inhibitors is dependent on their
speciﬁcity, and it will be important to conﬁrm the importance
of the CaMKKs in muscle using knockout mice.4. AMPK – regulation by adipokines
Although AMPK orthologues are present in single-celled
eukaryotes and the kinase is clearly involved in regulating en-
ergy balance at the cellular level in multicellular eukaryotes,
exciting recent developments have shown that in the latter it
also regulates energy balance at the whole body level via its
modulation by hormones and cytokines. Leptin, the classical
‘‘adipokine’’ released from adipocytes, which appears to signal
a suﬃciency of fat stored in adipose tissue, stimulates the a2
isoform of AMPK and hence fatty acid oxidation in skeletal
muscle [27]. By this means leptin increases whole body energy
expenditure, along with its better-known ability to inhibit en-
ergy intake by suppressing appetite. Intriguingly, leptin has
glucose
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glycolysis
fatty acid
oxidationgluconeogenesis
mTOR activation
protein synthesis
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ventricular regions of the hypothalamus, and there is evidence
that this is involved in the ability of leptin to suppress appetite
[28]. Consistent with this, agents that stimulate AMPK in the
hypothalamus, such as the drug AICA riboside, the gut hor-
mone ghrelin, and cannabinoids, all increase food intake in ro-
dents [29,30]. Leptin and other anorexigenic signals like insulin
are thought to cause release of melanocortin-4 (MC4) from
pro-opiomelanocortin (POMC) expressing neurones, stimulat-
ing in turn anorexigenic neurones expressing the MC4 recep-
tor. In addition, the anorexigenic signals are thought to
inhibit agouti-related protein (AgRP) expressing neurones that
antagonize the MC4 receptor-neurones [28]. A problem with
the studies that have measured AMPK activity in the hypo-
thalamus is that even very small regions dissected from it con-
tain many diﬀerent types of neurone that might be responding
to the various stimuli in a heterogeneous manner. In an at-
tempt to overcome this problem, the a2 isoform of AMPK
has been speciﬁcally knocked out using the Cre-loxP system
in POMC- and AgRP-expressing neurones of mice [31].
Knocking out a2 in these neurones might have been expected
to mimic the eﬀects of leptin to generate a lean phenotype.
However, contrary to expectations, mice in which a2 was
knocked out in POMC neurones exhibited mild obesity as they
aged, and the electrophysiological response of the POMC neu-
rones to leptin and insulin were normal. Moreover, these mice
exhibited a normal response to leptin, and an MC4 receptor
agonist, in terms of reductions in food intake and body weight.
Crossing with AMPK-a1 knockout mice ruled out the possibil-
ity that the lack of eﬀects were due to compensation by that
isoform. In contrast to the results with the POMC knockouts,
and more in line with what might have been expected, mice in
which a2 was knocked out in AgRP neurones exhibited a lean
phenotype. However, the electrophysiological responses of the
neurones to insulin were preserved. While these results do not
support models that propose that AMPK is a key central reg-
ulator of food intake in the hypothalamus, interesting addi-
tional ﬁndings were that neither POMC nor AgRP neurones
from the knockouts hyperpolarized in response to low glucose,
unlike equivalent neurones from wild type mice [31]. This sug-
gests that, although AMPK may not be directly involved in the
response of the hypothalamus to hormones like leptin and
insulin, it may be involved in the response to hypoglycaemia.
Indeed, there is evidence using pharmacological agents that
AMPK activation in the hypothalamus can modify the re-
sponse to a subsequent episode of hypoglycaemia [32,33].
Another major adipokine, adiponectin, has also been re-
ported to activate AMPK in muscle and in liver [34,35], and
experiments in which a dominant negative mutant of AMPK
was expressed via an adenovirus vector suggest that hepatic
AMPK is required for the ability of adiponectin to lower plas-
ma glucose by suppressing gluconeogenesis [34]. Although
adiponectin receptors have been characterized [36], the de-
tailed mechanisms by which adiponectin (and leptin) regulate
AMPK activity remains unclear.mitochondrial
biogenesis
fatty acid
synthesis
cholesterol
synthesis
Fig. 3. Pathways relevant to the metabolic syndrome that are activated
or inhibited by AMPK activation.5. AMPK – targets relevant to the metabolic syndrome
A complete description of the downstream targets for
AMPK are beyond the scope of this review, and those inter-
ested should refer to another recent review [3]. Some of thepathways most relevant to the metabolic syndrome that are
modulated in response to AMPK activation are shown in
Fig. 3. In general, AMPK up-regulates catabolic pathways
that generate ATP, while down-regulating anabolic pathways
that consume ATP. A key eﬀect is up-regulation of glucose up-
take, by increased translocation of the transporter glucose
transporter-4 (GLUT4) to the plasma membrane [37], by acti-
vation of GLUT1 at the plasma membrane [38], and by in-
creased transcription of the GLUT4 gene [39]. The latter
eﬀect may be responsible for the increased expression of this
transporter in response to endurance training, which can lead
in turn to increased insulin-stimulated glucose uptake. Since
reduced insulin-stimulated glucose uptake via GLUT4 is a
key feature of insulin resistance, the mechanism by which exer-
cise and AMPK activation stimulate this process in an insulin-
independent manner is of great interest. Studies with various
transgenic mouse models where AMPK activation is reduced
suggest that AMPK plays a major role in the eﬀects of contrac-
tion on glucose uptake, although other, parallel pathways also
appear to be involved [23,40,41]. The exact mechanism by
which AMPK stimulates GLUT4 translocation is not known,
but it may involve phosphorylation of Akt substrate of
160 kDa (AS160), a protein involved in traﬃcking of GLUT4
vesicles [42,43].
The high fasting glucose in subjects with type 2 diabetes re-
sults from a reduced ability of insulin to repress glucose pro-
duction by the liver, as well as a reduced ability of the
hormone to increase glucose uptake in the periphery. AMPK
activation in hepatoma cells down-regulates expression of the
gluconeogenic enzymes phosphoenolpyruvate carboxykinase
and glucose-6-phosphatase [44], and activation of AMPK is
thought to underlie the ability of adiponectin to reduced hepa-
tic glucose production [34]. Recently, it has been proposed that
a key target of AMPK that mediates this eﬀect is transcrip-
tional co-activator, TORC2, which translocates to the cyto-
plasm in response to phosphorylation by AMPK [45].
In terms of lipid metabolism, AMPK activation both inhib-
its fatty acid synthesis and stimulates fatty acid oxidation, thus
reducing excessive storage of triglycerides, which in cells other
than adipocytes is strongly associated with insulin resistance, a
phenomenon known as ‘‘lipotoxicity’’ [46]. AMPK inhibits
fatty acid synthesis both acutely by phosphorylating and inac-
tivating the ACC1 isoform of acetyl-CoA carboxylase [47], and
in the longer term by switching oﬀ expression of lipogenic
genes including ACC1 and fatty acid synthase [48]. It stimu-
lates fatty acid oxidation by phosphorylating and inactivating
the ACC2 isoform of acetyl-CoA carboxylase, lowering malo-
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uptake into mitochondria [49]. All of these eﬀects would tend
to lower plasma fatty acids and triglycerides, with elevated tri-
glycerides being one facet of the metabolic syndrome. Another
potential mechanism to lower plasma fatty acids is the ability
of AMPK to antagonize catecholamine-stimulated lipolysis in
adipocytes [47,50].
An additional catabolic action of AMPK is its ability to pro-
mote mitochondrial biogenesis by up-regulating the expression
of peroxisome proliferator-activated receptor-c (PPAR-c) co-
activator-1a (PGC-1a) [51]. Once again this would be beneﬁ-
cial in insulin resistant states because a relative deﬁcit in mito-
chondrial function is thought to predispose to development of
type 2 diabetes [52].
Finally, AMPK activation inhibits activation of the mam-
malian target-of-rapamycin pathway by the insulin/insulin-like
growth factor-1 pathway, probably via phosphorylation of
TSC2, an upstream regulator of mTOR [53]. Since the insu-
lin-mTOR pathway is thought to exert a feedback eﬀect on
insulin signalling via activation of S6 kinase I and consequent
phosphorylation and down-regulation of insulin receptor sub-
strate-1 (IRS1) [54–56], AMPK activation should increase sub-
sequent insulin sensitivity by inhibiting mTOR. It is possible
that this eﬀect explains the ability of AMPK activators to mi-
mic the eﬀect of a single bout of muscle contraction to increase
muscle insulin sensitivity [57].6. Pharmacological activators of AMPK as treatments for
diabetes and the metabolic syndrome
The eﬀects described in the previous section make it fairly
obvious that activators of AMPK may be eﬀective in treatment
of type 2 diabetes and the metabolic syndrome, and perhaps
even obesity. The ﬁrst compound shown to activate AMPK
in intact cells and in vivo was the nucleoside 5-aminoimidaz-
ole-4-carboxamide riboside (AICAR) [47], which was shown
to reverse insulin resistance and many other aspects of the met-
abolic syndrome in animal models such as the ob/ob mouse
[58], the fa/fa rat [59,60] and the high fat-fed rat [61]. At about
the same time, it was shown that the biguanide drug metformin
activated AMPK in intact cells [62]. Metformin is a derivative
of galegine, one of the active constituents of the ancient herbal
remedy, French Lilac (Gallega oﬃcinalis). With its sister bigua-
nide, phenformin (which was withdrawn due to the serious side
eﬀect of lactic acidosis), it has been used to treat type 2 diabe-
tes for 50 years, and is currently the front-line drug for this dis-
order, being prescribed to more than 120 million subjects
worldwide. Metformin does not activate AMPK directly, or
regulate its phosphorylation or dephosphorylation, in cell-free
assays [63], and may instead work indirectly by inhibiting the
respiratory chain (see below). The concentrations of metfor-
min required to generate a large activation of AMPK in cul-
tured cells are also rather high (1–10 mM, rather than the
10–20 lM estimated in human plasma after therapeutic doses),
but this can be explained in part by the fact that the organic
cation transporter organic cation transporter-1 (OCT1), which
is not expressed in many cultured cells, facilitates entry of the
drug into cells. OCT1 is particularly expressed in the liver, and
results in 25% of the total dose being found in the liver 10 min
after intravenous administration to wild type mice, as against
<1% in OCT1 (/) mice [64]. The key role of liver AMPKin the response to metformin was emphasized by ﬁndings that
in mice with a ‘‘ﬂoxed’’ LKB1 gene, in which the upstream ki-
nase was knocked out in those cells by infection with adenovi-
rus expressing Cre recombinase, the glucose lowering eﬀect of
mice rendered hyperglycaemic using a high-fat diet was abol-
ished [65].
Another class of drugs that is currently widely used to treat
type 2 diabetes is the thiazolidinediones, such as rosiglitazone
and pioglitazone, both of which were reported to activate
AMPK in intact cells [66,67]. Like the biguanides, the thiazo-
lidinediones do not activate AMPK directly, and both classes
of drug may achieve this indirectly by inhibiting complex I
of the respiratory chain (explaining the side eﬀect of lactic aci-
dosis produced by phenformin) and thus increasing the cellular
AMP:ATP ratio [68–70]. However, it is generally believed that
the major target of the thiazolidinediones is the transcription
factor PPAR-c [71]. A major eﬀect of thiazolidinedione action
on PPAR-c in adipocytes is to stimulate release of adiponectin,
and the eﬀects of the drugs to reverse insulin resistance and im-
prove glucose tolerance in high-fat fed rats are greatly reduced
in adiponectin knockout mice [72,73]. Since adiponectin now
appears to act on its target cells primarily by activating
AMPK, the thiazolidinediones may therefore exert their ther-
apeutic beneﬁts in part via two independent eﬀects to activate
AMPK.7. AMPK – mutations that give rise to heart disease
The c subunits of AMPK and its orthologues contain four
tandem repeats of a sequence motif ﬁrst recognized by Bat-
eman [74] and known as a CBS motif. These motifs, which oc-
cur in a small number of proteins other than the c subunits,
occur in pairs to form the so-called Bateman domains, which
have been shown in various diﬀerent proteins to bind ligands
containing adenosine, i.e. AMP, ATP or S-adenosylmethio-
nine [75]. The four CBS repeats in the AMPK c subunits form
two Bateman domains, each of which binds one molecule of
AMP or ATP in a mutually exclusive manner. Great interest
in the c subunits was aroused when it was reported that point
mutations in the c2 isoform, which is expressed in both cardiac
and skeletal muscle, caused heart disease in humans [76]. Most
cause an adult onset form of ventricular pre-excitation (Wolﬀ–
Parkinson–White syndrome), i.e. a premature excitation of the
large chambers of the heart (ventricles) due to abnormal elec-
trical connections with the small chambers (atria), which is
inherited in an autosomal dominant manner. Two particularly
severe mutations (R531Q and R384T) appear to be de novo
mutations that are not inherited because even in the heterozy-
gote they cause death from heart failure or respiratory prob-
lems within the ﬁrst few weeks or months of life [77,78].
What is the eﬀect of these mutations on the regulation of
AMPK? They all reduce the activation of the AMPK complex
by AMP, and reduce the binding of AMP to the isolated Bat-
eman domains [75,77–79]. Indeed, this provided the crucial evi-
dence that the Bateman domains represent the regulatory
nucleotide-binding sites on the abc complex. Recently, a crys-
tal structure of the AMPK orthologue from the yeast S. pombe
has provided insight into the nature of these binding sites and
the eﬀects of the mutations [80]. The entire abc complex would
not form suitable crystals, so limited proteolysis was used to
identify the core of the complex, comprising only the C-termi-
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former) and the entire c subunit. Constructs encoding this core
complex were then crystallized in the presence of AMP or
ATP. In the structures the two Bateman domains face each
other in a quasi-symmetrical manner (Fig. 4), and the C-termi-
nal domain (formed by CBS3 and CBS4) contained a single
molecule of AMP or ATP bound in the same site. Interest-
ingly, the positively charged side chain of an arginine residue
(Arg-290 in CBS4, equivalent to Arg-531 in human c2) forms
an ionic interaction with phosphate groups of AMP or ATP.
The ﬁnding that there was no nucleotide in the equivalent site
within the N-terminal domain (formed by CBS1 and CBS2)
was somewhat surprising, because the isolated N-terminal Bat-
eman domain from human c2 had been shown to bind AMP or
ATP [75]. However, this may be a genuine species diﬀerence.
Basic residues in CBS1 and CBS2 of human c2 (Arg-302 and
His-383) that are in the equivalent position to Arg-531 in
CBS4, and which (like Arg-531) reduce AMP activation and
give rise to ventricular pre-excitation when mutated in hu-
mans, are not conserved in the c subunit sequences from S.
pombe or the budding yeast, S. cerevisiae. The latter is not acti-
vated by AMP [81], and this does not appear to have been
tested with the S. pombe complex. If it is assumed that both
Bateman domains can be occupied by nucleotide in the human
c subunit then, satisfyingly, eight out of ten residues where
mutations have been found to be associated with ventricular
pre-excitation in human c2 are located directly within the
two nucleotide binding sites. This includes four basic residues
(Arg-302 in CBS1, His-383 and Arg-384 in CBS2, and Arg-531
in CBS4) whose side chains may bind the phosphate groups of
the nucleotides.Fig. 4. Close-up of the crystal structure of the S. pombe orthologue of
AMPK [80], showing the c subunit with the symmetrical layout of the
CBS repeats, the bound AMP and the side chain of Arg-290
interacting with the phosphate group of AMP. The picture was
created using MacPyMol, with the polypeptide backbones in ‘‘ribbon’’
representation. AMP and the Arg-290 side chain are in ‘‘stick’’
representation with carbon atoms in green, nitrogen in blue, oxygen in
red and phosphorus in purple (hydrogen omitted). The AMP molecule
is oriented in this view with the adenine at the bottom and the
phosphate at the top. It lies in the hydrophobic cleft between CBS3
and CBS4; the equivalent cleft between CBS1 and CBS2 is unoccupied
in the S. pombe structure.Another interesting ﬁnding with the S. pombe structure was
that there was no Mg2+ ion in the complex crystallized with
ATP, even though high concentrations of the metal ion had
been included in the medium. Unlike AMP, ATP binds
Mg2+ tightly such that under physiological conditions the cel-
lular concentration of free ATP is around two orders of mag-
nitude lower than that of the MgATP complex. Since it
appears to be free ATP that binds to the c subunits, this ex-
plains how AMP is able to compete with ATP for binding at
the regulatory sites. The total cellular concentration of AMP
is usually 100-fold lower than that of ATP, but the concentra-
tions of the free nucleotides will be much more comparable.
Why do mutations that interfere with the binding of AMP
and ATP to the c subunit give rise to heart disease, and specif-
ically ventricular pre-excitation? A metabolic defect that ap-
pears to be universally associated with these mutations is the
abnormal accumulation of glycogen in the cardiac myocytes,
which is hypothesized to interfere with the development of
the electrically insulating layer between the atria and ventricles
[76]. Defective binding of the activator AMP represents a loss-
of-function eﬀect, but the mutations also cause defective bind-
ing of the inhibitor, ATP [75]. Although the c2 isoform is ex-
pressed at higher levels in the heart than elsewhere, defective
activation by AMP may be compensated for by other iso-
forms, especially c1. However, defective inhibition by ATP
may give rise to an increased basal activation state of the c2
complex [77], a gain-of-function eﬀect that would explain
why these mutations are dominant in character. Increased ba-
sal activity may lead to increased glucose uptake, leading in
turn to excessive glycogen accumulation. Consistent with this
hypothesis, transgenic mice that over-express one of the c2
mutations (N488I) in cardiac muscle exhibited elevated glucose
uptake and fatty acid oxidation in the heart. The elevated glu-
cose uptake, in the absence of a real increased demand for glu-
cose, caused an increase in the cellular glucose-6-phosphate
concentration that would stimulate glycogen synthase and
hence glycogen synthesis [82]. This adverse eﬀect of an increase
in the basal activity of AMPK in the heart raises the question
of whether drugs that achieved the same eﬀect might also have
adverse eﬀects on that organ. Could it be that this accounts for
the recent report [83] of a marginally elevated risk of death
from cardiovascular causes in patients treated with the thiazo-
lidinedione, rosiglitazone?8. Conclusions and future prospects
The ﬁndings that AMPK is activated by metformin [62], and
is the likely therapeutic target for the drug [65], provided the
ﬁnal ‘‘proof of concept’’ that AMPK activators can be eﬀective
treatments for type 2 diabetes. However, metformin does not
activate AMPK directly [63], and instead appears to act indi-
rectly by inhibiting Complex I of the respiratory chain
[69,70]. This mechanism of action is likely to explain the life-
threatening side eﬀect of lactic acidosis that led to the with-
drawal of the sister drug, phenformin, from human use. While
lactic acidosis is much less common during metformin treat-
ment it can still occur, and there is evidence from animal stud-
ies that much of the lactic acid produced is derived from the
gut [84]. Due to its oral administration, intestinal mucosal cells
would experience the highest concentrations of the drug, and
they express OCT1 and other related transporters that may
D.G. Hardie / FEBS Letters 582 (2008) 81–89 87be responsible for its intestinal uptake [85]. Interestingly, the
main side eﬀects of metformin (e.g. nausea, vomiting,
ﬂatulence, and anorexia) are gastrointestinal, and may
perhaps be caused by inhibition of the respiratory chain in
the intestine.
This raises the question of whether a drug that directly acti-
vated AMPK, perhaps by mimicking the eﬀect of AMP, would
remain eﬃcacious while avoiding these side-eﬀects of phenfor-
min and metformin. A prototype of such a drug is the com-
pound A-769662, developed by Abbott laboratories by
screening for AMPK activators. In animal models of the met-
abolic syndrome such as the ob/ob mouse, this compound had
many of the eﬀects expected for an AMPK activator, such as
lowering blood glucose and triglycerides, lowering liver trigly-
cerides, down-regulating gluconeogenic genes, and even reduc-
ing weight gain [86]. Unfortunately, the oral availability of this
compound was poor and it was administered to the animals by
injection, but it may nevertheless indicate the way forward.
One caveat is that it will be important to determine whether
drugs that activate AMPK and thus increase glucose uptake,
in the absence of a real demand for the nutrient, might cause
adverse eﬀects in the heart such as are observed with the acti-
vating mutations in complexes containing c2. Time alone will
tell.
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